NCT00190489View on ClinicalTrials.gov

A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

January 31, 1999

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Breast CancerNeoplasm Metastasis
Interventions
DRUG

AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles

DRUG

Docetaxel 60mg/m2 every 21 days for 6 cycles

DRUG

AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles

Trial Locations (1)

104-0045

National Cancer Center Hospital, Chuo-ku, Tsukiji, 5-1-1

All Listed Sponsors
collaborator

Ministry of Health, Labour and Welfare, Japan

OTHER_GOV

lead

Japan Clinical Oncology Group

OTHER

NCT00190489 - A Trial of Doxorubicin/Cyclophosphamide (AC), Docetaxel (D), and Alternating AC and D for Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter